secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001213900-25-019779
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharma FY2024 net loss $13.2M, cash $3.8M; FDA confirms AD04 505(b)(2) path
--------------------------------------------------------------------------------

- Net loss $13.2M in FY2024 versus $5.1M in FY2023; widened primarily on $4.5M non-cash inducement charge.
- Cash and equivalents $3.8M at year-end; expects to fund operations into H2 2025.
- R&D spend rose $1.9M (+155%) driven by PK study and CMC manufacturing for AD04 Phase 3.
- FDA confirmed 505(b)(2) bridging strategy; Phase 3 trial to begin in 2025.
- Appointed Vinay Shah as CFO in November 2024; secured three new U.S. patents for AD04 genetic diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025019779/0001213900-25-019779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025019779/ea0232881-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-019779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer